|
[1]
|
Pandey, A., Akhtar, J., Khan, M.I., Ahmad, M. and Islam, A. (2026) Impact of Angiopoietin-Like 4 (ANGPTL4) Protein and O-Linked β-N-Acetylglucosamine(O-GlcNAc) in Diabetic Nephropathy. Diabetes Research and Clinical Practice, 235, Article 113211. [Google Scholar] [CrossRef]
|
|
[2]
|
Wang, X., Li, S., Ge, X., Xie, T., Li, S., Yuan, R., et al. (2026) Advances in Understanding the NLRP3 Inflammasome‑Mediated Mechanisms and Therapeutic Targets in Diabetic Nephropathy (Review). International Journal of Molecular Medicine, 58, 1-23. [Google Scholar] [CrossRef]
|
|
[3]
|
Umanath, K. and Lewis, J.B. (2018) Update on Diabetic Nephropathy: Core Curriculum 2018. American Journal of Kidney Diseases, 71, 884-895. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Alicic, R.Z., Rooney, M.T. and Tuttle, K.R. (2017) Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clinical Journal of the American Society of Nephrology, 12, 2032-2045. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B.B., et al. (2022) IDF Diabetes Atlas: Global, Regional and Country-Level Diabetes Prevalence Estimates for 2021 and Projections for 2045. Diabetes Research and Clinical Practice, 183, Article 109119. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Tuttle, K.R., Agarwal, R., Alpers, C.E., Bakris, G.L., Brosius, F.C., Kolkhof, P., et al. (2022) Molecular Mechanisms and Therapeutic Targets for Diabetic Kidney Disease. Kidney International, 102, 248-260. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Kristensen, S.L., Rørth, R., Jhund, P.S., Docherty, K.F., Sattar, N., Preiss, D., et al. (2019) Cardiovascular, Mortality, and Kidney Outcomes with GLP-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Cardiovascular Outcome Trials. The Lancet Diabetes & Endocrinology, 7, 776-785. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Thomas, H.Y. and Ford Versypt, A.N. (2022) Pathophysiology of Mesangial Expansion in Diabetic Nephropathy: Mesangial Structure, Glomerular Biomechanics, and Biochemical Signaling and Regulation. Journal of Biological Engineering, 16, Article No. 19. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Raleigh, M.J., Pasricha, S.V., Nauth, A., Ward, M.R. and Connelly, K.A. (2024) Endothelial Progenitor Cells for Diabetic Cardiac and Kidney Disease. Stem Cells Translational Medicine, 13, 625-636. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Wang, Y., Lin, T., Lu, J., He, W., Chen, H., Wen, T., et al. (2025) Trends and Analysis of Risk Factor Differences in the Global Burden of Chronic Kidney Disease Due to Type 2 Diabetes from 1990 to 2021: A Population-Based Study. Diabetes, Obesity and Metabolism, 27, 1902-1919. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
He, G., Liu, J., Lin, Y., Qi, J., Hu, J., Yin, P., et al. (2025) Chronic Kidney Disease Burden from 1990 to 2023 in China: National and Provincial Insights from the Global Burden of Diseases Study 2023. The Lancet Regional Health—Western Pacific, 68, Article 101776. [Google Scholar] [CrossRef]
|
|
[12]
|
Hu, H., Liang, W. and Ding, G. (2024) Ion Homeostasis in Diabetic Kidney Disease. Trends in Endocrinology & Metabolism, 35, 142-150. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Liu, S., Liu, J., Ang, K., Lee, J., Chan, C., Gurung, R.L., et al. (2024) Incident Heart Failure and the Subsequent Risk of Progression to End Stage Kidney Disease in Individuals with Type 2 Diabetes. Cardiovascular Diabetology, 23, Article No. 204. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Mohammedi, K., Marre, M. and Alhenc-Gelas, F. (2024) Genetic Predisposition to Nephropathy and Associated Cardiovascular Disease in People with Type 1 Diabetes: Role of the Angiotensini-Converting Enzyme (ACE), and beyond; A Narrative Review. Cardiovascular Diabetology, 23, Article No. 453. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Mentz, R.J., Brunton, S.A. and Rangaswami, J. (2023) Sodium-Glucose Cotransporter-2 Inhibition for Heart Failure with Preserved Ejection Fraction and Chronic Kidney Disease with or without Type 2 Diabetes Mellitus: A Narrative Review. Cardiovascular Diabetology, 22, Article No. 316. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Smeijer, J.D., Kohan, D.E., Rossing, P., Correa-Rotter, R., Liew, A., Tang, S.C.W., et al. (2023) Insulin Resistance, Kidney Outcomes and Effects of the Endothelin Receptor Antagonist Atrasentan in Patients with Type 2 Diabetes and Chronic Kidney Disease. Cardiovascular Diabetology, 22, Article No. 251. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
van der Hoef, C.C.S., Boorsma, E.M., Emmens, J.E., van Essen, B.J., Metra, M., Ng, L.L., et al. (2023) Biomarker Signature and Pathophysiological Pathways in Patients with Chronic Heart Failure and Metabolic Syndrome. European Journal of Heart Failure, 25, 163-173. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Ma, T., Li, X., Zhu, Y., Yu, S., Liu, T., Zhang, X., et al. (2022) Excessive Activation of Notch Signaling in Macrophages Promote Kidney Inflammation, Fibrosis, and Necroptosis. Frontiers in Immunology, 13, Article 835879. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Zhu, L., Liu, Z., Liu, J., Li, Z., Bao, Y., Sun, X., et al. (2025) NCOA4 Linked to Endothelial Cell Ferritinophagy and Ferroptosis: A Key Regulator Aggravate Aortic Endothelial Inflammation and Atherosclerosis. Redox Biology, 79, Article 103465. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Zheng, D., Liu, J., Piao, H., Zhu, Z., Wei, R. and Liu, K. (2022) ROS-Triggered Endothelial Cell Death Mechanisms: Focus on Pyroptosis, Parthanatos, and Ferroptosis. Frontiers in Immunology, 13, Article 1039241. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Jiang, T., Chen, R., Chang, J., Duan, J., Wang, Y., Sun, Y., et al. (2026) Unveiling the Immune Microenvironment in Diabetic Nephropathy: From Mechanisms to Therapeutics. Frontiers in Immunology, 17, Article 1750484. [Google Scholar] [CrossRef]
|
|
[22]
|
Cheng, G., Liu, Y., Guo, R., Wang, H., Zhang, W. and Wang, Y. (2024) Molecular Mechanisms of Gut Microbiota in Diabetic Nephropathy. Diabetes Research and Clinical Practice, 213, Article 111726. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Wang, Z., Wu, C., Yin, D. and Dou, K. (2025) Ferroptosis: Mechanism and Role in Diabetes-Related Cardiovascular Diseases. Cardiovascular Diabetology, 24, Article No. 60. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Ma, Y., Gao, J., Sun, Y., Gu, Y., Zhang, L., Zhen, Y., et al. (2026) Convergence of ER Stress and Ferroptosis in Diabetic Vasculopathy: Therapeutic Protection by Ferrostatin-1. Biochemical Pharmacology, 250, Article 117998. [Google Scholar] [CrossRef]
|
|
[25]
|
Wang, Y.H., Chang, D.Y., Zhao, M.H. and Chen, M. (2024) Dapagliflozin Alleviates Diabetic Kidney Disease via Hypoxia Inducible Factor 1α/Heme Oxygenase 1-Mediated Ferroptosis. Antioxidants & Redox Signaling, 40, 492-509. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Tsai, Y.C., Huang, J.C., Yu, P.S., et al. (2025) Sodium-Glucose Cotransporter 2 Inhibitors Ameliorate Glutathione Cysteine Ligase Modifier-Mediated Oxidative Stress and Subsequent Ferroptosis in Proximal Tubules of Diabetic Kidney Disease. Redox Report, 30, Article 2528334. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Sarraju, A., Bakris, G., Cannon, C.P., Cherney, D., Damaraju, C.V., Figtree, G.A., et al. (2022) Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria. Journal of the American College of Cardiology, 80, 1721-1731. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Bhatt, D.L., Verma, S. and Pitt, B. (2021) Emperor-Preserved: A Promise Fulfilled. Cell Metabolism, 33, 2099-2103. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Kondo, T., Butt, J.H., Curtain, J.P., Jhund, P.S., Docherty, K.F., Claggett, B.L., et al. (2023) Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and Deliver. Circulation: Heart Failure, 16, e010898. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Butt, J.H., Docherty, K.F., Jhund, P.S., de Boer, R.A., Böhm, M., Desai, A.S., et al. (2022) Dapagliflozin and Atrial Fibrillation in Heart Failure with Reduced Ejection Fraction: Insights from DAPA-HF. European Journal of Heart Failure, 24, 513-525. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Docherty, K.F., Simpson, J., Jhund, P.S., Inzucchi, S.E., Køber, L., Kosiborod, M.N., et al. (2022) Effect of Dapagliflozin, Compared with Placebo, According to Baseline Risk in DAPA-HF. JACC: Heart Failure, 10, 104-118. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Del Vecchio, L., Beretta, A., Jovane, C., Peiti, S. and Genovesi, S. (2021) A Role for SGLT-2 Inhibitors in Treating Non-Diabetic Chronic Kidney Disease. Drugs, 81, 1491-1511. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Chatur, S., Vaduganathan, M., Claggett, B.L., Mc Causland, F.R., Desai, A.S., Jhund, P.S., et al. (2023) Dapagliflozin in Patients with Heart Failure and Deterioration in Renal Function. Journal of the American College of Cardiology, 82, 1854-1863. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Razuk, V., Chiarito, M., Cao, D., Nicolas, J., Pivato, C.A., Camaj, A., et al. (2022) SGLT-2 Inhibitors and Cardiovascular Outcomes in Patients with and without a History of Heart Failure: A Systematic Review and Meta-Analysis. European Heart Journal—Cardiovascular Pharmacotherapy, 8, 557-567. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Cherney, D.Z.I., Belmar, N., Bjornstad, P., Chacko, M.M., Gunnarsson, T.P., Hodgin, J.B., et al. (2025) Rationale, Design and Baseline Characteristics of REMODEL, a Mechanism-of-Action Trial with Semaglutide in People with Type 2 Diabetes and Chronic Kidney Disease. Nephrology Dialysis Transplantation, 40, 2182-2192. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Ling, J. and Chow, E. (2024) Glucagon-Like Peptide Receptor-1 Receptor Agonists: The Emerging Fourth Pillar in Type 2 Diabetes and Chronic Kidney Disease? Med, 5, 845-847. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Lee, M.M.Y., Sattar, N., Pop-Busui, R., Deanfield, J., Emerson, S.S., Inzucchi, S.E., et al. (2025) Cardiovascular and Kidney Outcomes and Mortality with Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Trials. Diabetes Care, 48, 846-859. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Damman, K. and Testani, J. (2024) Cardiorenal Interactions in Heart Failure: Insights from Recent Therapeutic Advances. Cardiovascular Research, 120, 1372-1384. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Solomon, S.D., McMurray, J.J.V., Vaduganathan, M., Claggett, B., Jhund, P.S., Desai, A.S., et al. (2024) Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. New England Journal of Medicine, 391, 1475-1485. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Docherty, K.F., Henderson, A.D., Jhund, P.S., Claggett, B.L., Desai, A.S., Mueller, K., et al. (2025) Efficacy and Safety of Finerenone across the Ejection Fraction Spectrum in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial. Circulation, 151, 45-58. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Blum, M.F., Mehta, S., Surapaneni, A., Carrero, J.J., Zhang, D., Inker, L., et al. (2026) A Target Trial Emulation Study of SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Combination Therapy in Preventing Kidney Failure in Type 2 Diabetes. Clinical Journal of the American Society of Nephrology, 21, 437-445. [Google Scholar] [CrossRef]
|
|
[42]
|
Agarwal, R., Green, J.B., Heerspink, H.J.L., Mann, J.F.E., McGill, J.B., Mottl, A.K., et al. (2025) Combination Effect of Finerenone and Empagliflozin in Participants with Chronic Kidney Disease and Type 2 Diabetes Using a UACR Endpoint (CONFIDENCE) Trial: Baseline Clinical Characteristics. Nephrology Dialysis Transplantation, 40, 1559-1569. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Agarwal, R., Green, J.B., Heerspink, H.J.L., Mann, J.F.E., McGill, J.B., Mottl, A.K., et al. (2025) Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety with Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE Trial). Diabetes Care, 48, 1904-1913. [Google Scholar] [CrossRef]
|
|
[44]
|
Vaduganathan, M., Green, J.B., Heerspink, H.J.L., et al. (2025) Simultaneous Initiation of Finerenone and Empagliflozin across the Spectrum of Kidney Risk in the CONFIDENCE Trial. Nephrology Dialysis Transplantation, 41, 161-170. [Google Scholar] [CrossRef]
|
|
[45]
|
Mottl, A., Scott, C., Green, J.B., Heerspink, H.J.L., Mann, J.F.E., McGill, J.B., et al. (2025) Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both. Journal of the American Society of Nephrology, 37, 764-776. [Google Scholar] [CrossRef]
|
|
[46]
|
Elenjickal, E.J., Travlos, C.K., Luu, J., Lemay, S., Suri, R.S. and Mavrakanas, T.A. (2025) Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with and without Advanced CKD: Systematic Review and Meta-Analysis. Clinical Journal of the American Society of Nephrology, 20, 788-809. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Rossing, P., Filippatos, G., Agarwal, R., Anker, S.D., Pitt, B., Ruilope, L.M., et al. (2021) Finerenone in Predominantly Advanced CKD and Type 2 Diabetes with or without Sodium-Glucose Cotransporter-2 Inhibitor Therapy. Kidney International Reports, 7, 36-45. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
Amat-Santos, I.J., Sánchez-Luna, J.P., Abu-Assi, E., Melendo-Viu, M., Cruz-Gonzalez, I., Nombela-Franco, L., et al. (2022) Rationale and Design of the Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) Randomized Trial. European Journal of Heart Failure, 24, 581-588. [Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
Caruso, I. and Giorgino, F. (2022) SGLT-2 Inhibitors as Cardio-Renal Protective Agents. Metabolism, 127, Article 154937. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Agarwal, R., Correa-Rotter, R., Navaneethan, S.D., Fukami, K., Heerspink, H.J.L., Mann, J.F.E., et al. (2026) Acute eGFR Changes and Their Mediation of Albuminuria Reduction with Empagliflozin and Finerenone. Journal of the American Society of Nephrology, 1-10. [Google Scholar] [CrossRef]
|